FAP and osteoarthritis: For instance, a recent study has demonstrated the successful application of lipid nanoparticles loaded with FAP‐specific small interfering RNA (LNPs@FAP siRNA), which mitigated osteoarthritis progression through their sustained‐release properties.[20] This strategy offers promising avenues for developing slow‐release drugs and delivery platforms tailored for periodontal pockets.